Summary: H.R.7251 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for H.R.7251. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (12/11/2018)

Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.